Becotatug Vedotin after cancer treatment for high-risk nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests if a drug called Becotatug Vedotin can help prevent nasopharyngeal cancer from returning in patients who have already completed standard treatments and are at high risk of recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of nasopharyngeal cancer called non-keratinizing (WHO type II or III).
- Your cancer was high-risk stage T4N1M0 or Tany N2-3M0, or you had signs of remaining cancer after initial chemotherapy.
- You finished induction chemotherapy and chemoradiotherapy with the standard recommended regimen.
- No more than 6 weeks have passed since your last radiation treatment.
- You are generally up and about (ECOG performance status 0 or 1).
- Your blood counts, liver, and kidney function are adequate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, becotatug vedotin and sintilimab, for patients with a type of nasopharyngeal cancer that has spread to nearby lymph nodes but not to distant organs. It aims to see if this treatment can help control the disease.
This trial tests a new drug combination for people whose nasopharyngeal cancer has come back in the same area or nearby lymph nodes. The goal is to see if this treatment can shrink or control the cancer.
This trial tests a new drug called Becotatug Vedotin for people with locally advanced nasopharyngeal cancer whose tumor did not shrink enough after initial chemotherapy plus immunotherapy. If you qualify, you may receive this targeted therapy to help control the disease.
This trial tests a combination of three treatments—a targeted cancer drug (becotatug vedotin), an immunotherapy drug (PD-1 antibody), and radiation therapy—for nasopharyngeal cancer that has come back after initial treatment. The goal is to see if this combination can shrink the tumor and help you live longer.
This trial tests a combination of two drugs (becotatug vedotin and an anti-PD1 immunotherapy) as maintenance treatment after initial chemotherapy for advanced nasopharyngeal cancer that has spread or returned. It's for people whose disease has not progressed after standard first-line treatment.
This trial tests a combination of a new targeted cancer drug (becotatug vedotin), an immunotherapy (PD-1 blockade), and chemoradiotherapy for newly diagnosed advanced nasopharyngeal cancer that has spread to nearby lymph nodes. The goal is to improve outcomes for patients with this aggressive cancer type.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.